Akero Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $4 | $0 |
Gross Profit | 2 | -1 | ||
EBITDA | -69,333 | -69,571 | -68,809 | -71,458 |
EBIT | -69,575 | -68,824 | -71,459 | |
Net Income | -70,505 | -70,725 | -70,024 | -72,705 |
Net Change In Cash | 0 | 0 | 4 | 0 |
Free Cash Flow | -48,246 | -67,664 | -67,090 | -70,424 |
Cash | 220,449 | 185,922 | 340,238 | 316,065 |
Basic Shares | 81,721 | 78,656 | 70,573 | 69,442 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -18 | -29 | -260 | -100,886 |
EBITDA | -285,423 | -148,631 | -111,034 | -100,845 |
EBIT | -256,728 | -148,660 | -111,294 | -100,886 |
Net Income | -252,060 | -151,759 | -108,910 | -100,736 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 99,290 | -36,799 | ||
Free Cash Flow | -230,107 | -145,367 | -92,517 | -79,681 |
Cash | 340,238 | 234,207 | 249,773 | 150,483 |
Basic Shares | 67,136 | 52,568 | 38,984 | 34,827 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.86 |
2025-03-31 | -$0.90 |
2024-12-31 | -$0.99 |
